Trump Falsely Claims the “Deep State” Is Sabotaging Vaccine Research

The president’s latest coronavirus conspiracy theory targets his own FDA.

Donald Trump

Tasos Katopodis/CNP via ZUMA

The coronavirus is a rapidly developing news story, so some of the content in this article might be out of date. Check out our most recent coverage of the coronavirus crisis, and subscribe to the Mother Jones Daily newsletter.

President Donald Trump woke up bright and early Saturday morning and tweeted out a particularly toxic conspiracy theory. Members of the “deep state,” he complained, had infiltrated his own Food and Drug Administration and were sabotaging efforts by pharmaceutical companies to enroll patients in coronavirus drug trials—all to stop him from winning reelection.

Trump’s obviously false allegations echo comments he made earlier this week after top officials at the National Institutes of Health reportedly persuaded the FDA to delay its planned emergency authorization for a procedure using blood plasma containing antibodies from recovering COVID-19 patients to treat sick individuals. Convalescent plasma, which Trump has frequently touted, is viewed by many scientists as a promising treatment, but researchers have so far struggled to conduct studies that would prove that it at actually works.

Asked this week about the NIH and FDA’s decision, Trump lashed out. “It could be a political decision, because you have a lot of people over there that don’t want to rush things because they want to—they want to do it after November 3rd,” he told reporters. That allegation is completely baseless; there’s no evidence whatsoever that government scientists are plotting to delay COVID-19 treatments until after the election. In the case of plasma, the administration’s own experts, including Anthony Fauci, argued that there was simply not enough evidence to go forward, according to the New York Times.

Another story this week may shed some light on Trump’s paranoid attacks on his own health experts. On Sunday, Axios published a remarkable article detailing the president’s efforts to persuade the FDA to green-light an unproven oleander extract that, its backers insist, can cure COVID-19. In July, two board members from the company developing oleandrin—Andrew Whitney and MyPillow founder Mike Lindell—managed to secure an Oval Office meeting with the president. Lindell told Axios that during the meeting, Trump essentially told them, “The FDA should be approving it.” But the news site noted that FDA commissioner Stephen Hahn, who Trump tagged in his tweet Saturday, appeared to be resisting and that Whitney had “privately complained that the FDA has been dragging its feet.”

But that’s not evidence of a deep-state cabal sabotaging Trump’s electoral fortunes. Rather, it’s evidence that in spite of the president’s efforts, the FDA, at least in this case, seems to be doing what it is supposed to be doing: protecting Americans from unproven miracle cures pushed by politically connected companies.

There’s similarly no support for Trump’s claim that the FDA is improperly interfering with vaccine trials for political reasons. Just the opposite: On Thursday, Reuters reported that Peter Marks, a high-ranking FDA official, had said he would resign from the agency rather than acquiesce to hypothetical White House pressure to quickly approve a vaccine that had not been shown to be safe and effective.

Again, it sounds like FDA officials are just doing their jobs. They may also be attempting to avoid a repeat of the hydroxychloroquine fiasco, in which the agency authorized the emergency use of an unproven drug that Trump repeatedly touted as a solution to the coronavirus crisis. Hydroxychloroquine remains unproven, and in June, the FDA revoked its emergency use authorization, citing risks posed by the medication.

Two months later, Trump is still fuming. In a second tweet attacking the FDA Saturday, Trump insisted that “many doctors” disagree with the FDA’s decision on hydroxychloroquine.

AN IMPORTANT UPDATE ON MOTHER JONES' FINANCES

We need to start being more upfront about how hard it is keeping a newsroom like Mother Jones afloat these days.

Because it is, and because we're fresh off finishing a fiscal year, on June 30, that came up a bit short of where we needed to be. And this next one simply has to be a year of growth—particularly for donations from online readers to help counter the brutal economics of journalism right now.

Straight up: We need this pitch, what you're reading right now, to start earning significantly more donations than normal. We need people who care enough about Mother Jones’ journalism to be reading a blurb like this to decide to pitch in and support it if you can right now.

Urgent, for sure. But it's not all doom and gloom!

Because over the challenging last year, and thanks to feedback from readers, we've started to see a better way to go about asking you to support our work: Level-headedly communicating the urgency of hitting our fundraising goals, being transparent about our finances, challenges, and opportunities, and explaining how being funded primarily by donations big and small, from ordinary (and extraordinary!) people like you, is the thing that lets us do the type of journalism you look to Mother Jones for—that is so very much needed right now.

And it's really been resonating with folks! Thankfully. Because corporations, powerful people with deep pockets, and market forces will never sustain the type of journalism Mother Jones exists to do. Only people like you will.

There's more about our finances in "News Never Pays," or "It's Not a Crisis. This Is the New Normal," and we'll have details about the year ahead for you soon. But we already know this: The fundraising for our next deadline, $350,000 by the time September 30 rolls around, has to start now, and it has to be stronger than normal so that we don't fall behind and risk coming up short again.

Please consider pitching in before moving on to whatever it is you're about to do next. We really need to see if we'll be able to raise more with this real estate on a daily basis than we have been, so we're hoping to see a promising start.

—Monika Bauerlein, CEO, and Brian Hiatt, Online Membership Director

payment methods

AN IMPORTANT UPDATE ON MOTHER JONES' FINANCES

We need to start being more upfront about how hard it is keeping a newsroom like Mother Jones afloat these days.

Because it is, and because we're fresh off finishing a fiscal year, on June 30, that came up a bit short of where we needed to be. And this next one simply has to be a year of growth—particularly for donations from online readers to help counter the brutal economics of journalism right now.

Straight up: We need this pitch, what you're reading right now, to start earning significantly more donations than normal. We need people who care enough about Mother Jones’ journalism to be reading a blurb like this to decide to pitch in and support it if you can right now.

Urgent, for sure. But it's not all doom and gloom!

Because over the challenging last year, and thanks to feedback from readers, we've started to see a better way to go about asking you to support our work: Level-headedly communicating the urgency of hitting our fundraising goals, being transparent about our finances, challenges, and opportunities, and explaining how being funded primarily by donations big and small, from ordinary (and extraordinary!) people like you, is the thing that lets us do the type of journalism you look to Mother Jones for—that is so very much needed right now.

And it's really been resonating with folks! Thankfully. Because corporations, powerful people with deep pockets, and market forces will never sustain the type of journalism Mother Jones exists to do. Only people like you will.

There's more about our finances in "News Never Pays," or "It's Not a Crisis. This Is the New Normal," and we'll have details about the year ahead for you soon. But we already know this: The fundraising for our next deadline, $350,000 by the time September 30 rolls around, has to start now, and it has to be stronger than normal so that we don't fall behind and risk coming up short again.

Please consider pitching in before moving on to whatever it is you're about to do next. We really need to see if we'll be able to raise more with this real estate on a daily basis than we have been, so we're hoping to see a promising start.

—Monika Bauerlein, CEO, and Brian Hiatt, Online Membership Director

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate